Close Menu

NEW YORK – Shares of Twist Bioscience rose 12 percent in afternoon trading on the Nasdaq on speculation that the synthetic DNA manufacturer is close to settling a trade secrets lawsuit filed by Agilent Technologies.

The San Francisco-based company's stock opened Thursday trading at $26.83 and the shares rose sharply in mid-afternoon trade to $30.11.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.